瑞戈非尼软组织肉瘤案例:联合分析给药与毒性重要性
该研究提出用患病率方法联合报告靶向治疗的不良事件(AE)与药物给药情况,并以瑞戈非尼II期试验数据展示。结果显示3个月时仅4.6%无进展患者发生≥2级黏膜炎/口腔炎,但58.1%患者无此AE却减量或中断治疗,加权患病率可纳入给药维度评估获益-风险。
要点
- 传统AE报告未考虑剂量调整,可能低估毒性负担。
- 患病率方法可估计无进展患者在不同健康状态的概率。
- 加权患病率将给药维度纳入AE评估,辅助获益-风险判断。
核心结论
- 联合分析不良事件与药物给药对评估靶向治疗获益-风险至关重要。
- 加权患病率方法将给药维度纳入AE评估,可供监管与临床决策参考。
研究设计与样本
- 方法学论文,提出患病率与加权患病率方法,并用瑞戈非尼II期试验(NCT01900743)数据展示。
主要发现
- 3个月时仅4.6%无进展患者发生≥2级黏膜炎/口腔炎。
- 无此AE但减量或中断治疗的患者患病率为58.1%。
- 瑞戈非尼毒性特征与减量的加权患病率在对照组更高。
关键数值与推荐
- 患病率方法定义三种健康状态:状态1为AE且全剂量,状态2为AE且减量,状态3为无AE且减量。
- 加权患病率通过给不同健康状态分配效用权重来体现剂量调整对疗效的影响。
临床怎么用
- 临床评估靶向治疗毒性时应同时记录剂量调整与中断情况。
- 可采用加权患病率辅助解读疗效与毒性的平衡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Different methods have been proposed to analyze adverse events (AEs) associated with targeted therapies. While these AEs lead to dose adjustments for many patients, conventional reporting methods do not take drug administration into consideration. This paper underlines the importance of jointly reporting AEs and drug administration using prevalence, and proposes a complementary approach to reporting. PATIENTS AND METHODS: The prevalence method estimates the probability of progression-free patients being in a particular health state (state 1: AEs with full dose; state 2: AEs with reduced dose; state 3: no AEs with reduced dose) at different time points. To take into account the impact of dose adjustments on efficacy, the weighted prevalence method can be used by assigning utility weights to the different health states. The benefit of these methods was illustrated using data from a phase II trial of regorafenib. RESULTS: Only 4.6% of progression-free patients developed mucositis/stomatitis (grade ≥2) at 3 months. The prevalence of patients not experiencing this AE but whose dose was reduced or treatment interrupted was 58.1%. The weighted prevalence of the regorafenib toxicity profile and dose reduction was higher in the control arm. CONCLUSION: This case study confirms the importance of jointly analyzing AEs and drug administration. The weighted prevalence approach is an average score that incorporates the dimension of drug administration into AE assessment. This can be helpful for regulatory agencies as well as for clinicians to evaluate the benefit-risk ratio of therapies in their treatment choice. CLINICAL TRIAL: NCT01900743.
引用
- Longué M, Cabarrou B, Wallet J, et al. The importance of jointly analyzing treatment administration and toxicity associated with targeted therapies: a case study of regorafenib in soft tissue sarcoma patients. Ann Oncol. 2018. PMID: 29722789. doi:10.1093/annonc/mdy168
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。